Clinical outcomes of gastrointestinal stromal tumor in southern Thailand

Pornsuksiri, Kittima; Chewatanakornkul, Siripong; Kanngurn, Samornmas; Maneechay, Wanwisa; Chaiyapan, Walawee; Sangkhathat, Surasak

doi:10.4251/wjgo.v4.i11.216

Cited by 7 publications

(6 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In comparison, hepatectomy is as safe but with a better survival benefit. Table displays the outcomes of imatinib therapy alone for unresectable GISTs reported by various studies …”

Section: Discussionmentioning

confidence: 99%

Analysis of long‐term survival after hepatectomy for isolated liver metastasis of gastrointestinal stromal tumour

Cheung

Chok

Chan

et al. 2013

ANZ Journal of Surgery

View full text Add to dashboard Cite

show abstract

“…In comparison, hepatectomy is as safe but with a better survival benefit. Table displays the outcomes of imatinib therapy alone for unresectable GISTs reported by various studies …”

Section: Discussionmentioning

confidence: 99%

Analysis of long‐term survival after hepatectomy for isolated liver metastasis of gastrointestinal stromal tumour

Cheung

Chok

Chan

et al. 2013

ANZ Journal of Surgery

View full text Add to dashboard Cite

show abstract

“…One of the imatinib induced complications is the GI bleeding, such as GAVE (define). It can be due to the presence of residual tumor or to other less common etiologies [ 12 , 13 ]. A multitude of dermatological toxicities also occurs, from various acute rashes to Steven-Johnson syndrome [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

Pfetin as a Risk Factor of Recurrence in Gastrointestinal Stromal Tumors

Orita

Ito

Kushida

et al. 2014

BioMed Research International

View full text Add to dashboard Cite

Background. Despite complete resection of gastrointestinal stromal tumors (GIST), recurrent and/or metastatic disease occurs, often depending on the grade of malignancy. As such, markers are needed that accurately predict patients at high risk for recurrence. Previously our group reported Pfetin as a prognostic biomarker for GIST. In order to create an approach for predicting risk of recurrence, we incorporated Pfetin expression with clinicopathological data to produce a predictive model. Object. Forty-five patients with localized primary GIST were treated with complete gross surgical resection surgically at our institution between 1995 and 2010 were included. The majority of tumors originated in the stomach (38 cases), as well as small intestine (6 cases) and rectum (1 case). Method. (1) We performed retrospective analysis of the connection between Pfetin expression, clinicopathological data, and incidences of recurrence, using bivariate and multivariate analyses. (2) The reactivity of the monoclonal antibody against Pfetin was examined by immunohistochemistry. Pfetin. We have reported Pfetin, identified microarray technology, and compared between statistically different GISTs for good and poor prognoses and for prognostic marker. Results. There were 7 cases of recurrences. (1) By univariate analysis, tumor size, mitoses, exposure to abdominal cavity, and complete tumor removal predicted risk of recurrence. (2) Pfetin-negative cases were significantly related to recurrence (P = 0.002). Conclusions. This analysis demonstrates that lack of Pfetin expression is an additional predictor of recurrence in resected GIST. Further study may determine the role of this variable added to the current predictive model for selection of adjuvant therapy.

show abstract

“…Gastric cancer is the fourth most common cancer and second leading cause of cancer-related deaths worldwide ( 1 – 4 ). Although great efforts have been made, the current treatments for gastric cancer are still not efficacious ( 5 ).…”

Section: Introductionmentioning

confidence: 99%

YAP signaling in gastric cancer-derived mesenchymal stem cells is critical for its promoting role in cancer progression

Pan

Tian

Zhang

et al. 2017

International Journal of Oncology

View full text Add to dashboard Cite

Cancer-associated mesenchymal stem cells (MSCs) are critically involved in tumor development and progression. However, the mechanisms of action for MSCs in cancer remain largely unknown. Herein, we reported that the expression of Yes-associated protein 1 (YAP) was higher in gastric cancer derived mesenchymal stem cells (GC-MSCs) than that in bone marrow derived MSCs (BM-MSCs). YAP knockdown not only inhibited the growth, migration and invasion, and stemness of GC-MSCs, but also suppressed their promoting effect on gastric cancer growth in vitro and in vivo. In addition, the interference of YAP expression in GC-MSCs also attenuated the promoting role of gastric cancer cells in endothelial cell tube formation and migration. Mechanistically, YAP knockdown reduced the activation of β-catenin and its target genes in gastric cancer cells by GC-MSCs. Taken together, these findings suggest that YAP activation in GC-MSCs plays an important role in promoting gastric cancer progression, which may represent a potential target for gastric cancer therapy.

show abstract

Clinical outcomes of gastrointestinal stromal tumor in southern Thailand

Abstract: The overall outcomes of GIST can be predicted by risk-categorization. Surgery alone may not be a curative treatment for GIST. Response to targeted therapy is a crucial survival determinant in these patients.

Cited by 7 publications

References 28 publications

Analysis of long‐term survival after hepatectomy for isolated liver metastasis of gastrointestinal stromal tumour

Analysis of long‐term survival after hepatectomy for isolated liver metastasis of gastrointestinal stromal tumour

Pfetin as a Risk Factor of Recurrence in Gastrointestinal Stromal Tumors

YAP signaling in gastric cancer-derived mesenchymal stem cells is critical for its promoting role in cancer progression

Contact Info

Product

Resources

About